INTESTINAL METAGENOMIC FEATURE AS SELECTION MARKER OF CURATIVE EFFECT OF ACARBOSE FOR TREATING TYPE 2 DIABETES

摘要

The present invention discloses a marker of characteristics of gut metagenome for screening the Acarbose efficacy in patients with Type 2 diabetes; the characteristic of gut microbiota metagenome is the Bacteroides enterotype. In the invention, it is discovered that patients with Type 2 diabetes with different gut microbiota showed significant difference in the therapeutic response to diabetic hypoglycemic agent-Acarbose by using the concept of enterotype firstly. Therefore, before medication, patients can be classified according to the enterotype, to select the populations with optimal efficacy and determine if an individual patient with Type 2 diabetes is applicable to Acarbose treatment. In addition, the classification of enterotypes is generally based on DNA sequencing or PCR amplification of parasites in the feces; while in the baseline, the bile acid component, especially secondary bile acid, can be used for distinguishing the enterotypes; the enterotype can be identified by the blood markers, to become a marker for diagnosis.